AI Article Synopsis
- The study evaluated the effectiveness and safety of nedaplatin-based chemotherapy for patients with advanced cervical cancer.
- Five clinical studies involving 264 patients were analyzed, revealing a pooled response rate of 74.6%, with common side effects including low white blood cell counts and nausea.
- Overall, nedaplatin-based regimens showed promising results in treating advanced cervical cancer without any reported treatment-related deaths.
Article Abstract
Purpose: This systematic analysis was conducted to evaluate the efficacy and safety of nedaplatin based salvage chemotherapy for treatment of patients with advanced cervical cancer.
Methods: Clinical studies evaluating the efficacy and safety of nedaplatin based regimens on response and safety for patients with cervical cancer were identified using a predefined search strategy. Pooled response rates (RRs) were calculated.
Results: For nedaplatin based regimens, 5 clinical studies including 264 patients with advanced cervical cancer were considered eligible for inclusion. The analysis showed that, in all patients, pooled RR was 74.6% (197/264). Major adverse effects were leukopenia, thrombocytopenia and nausea/vomiting. No treatment related death occurred with nedaplatin based treatment.
Conclusion: This systematic analysis suggests that nedaplatin based regimens are associated with good activity with acceptable tolerability in treating patients with advanced cervical cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7314/apjcp.2015.16.8.3159 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review.
Front Oncol
December 2024
Department Oncology, Yidu Central Hospital of Weifang, Weifang, China.
Article Synopsis
- Lung cancer is the leading cancer globally, with EGFR mutations common in female NSCLC patients, necessitating targeted therapies like TKIs, though resistance often develops.
- A case study details a 63-year-old woman with both lung adenocarcinoma and renal cancer; she initially responded well to standard treatments but faced resistance.
- The use of furmonertinib, a third-generation EGFR-TKI, resulted in a remarkable 27 months of progression-free survival, showcasing its effectiveness against complex resistance pathways.
What is the Reason That the Pharmacological Future of Chemotherapeutics in the Treatment of Lung Cancer Could Be Most Closely Related to Nanostructures? Platinum Drugs in Therapy of Non-Small and Small Cell Lung Cancer and Their Unexpected, Possible Interactions. The Review.
Int J Nanomedicine
September 2024
Department of Physical Chemistry, Faculty of Pharmacy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Over the course of several decades, anticancer treatment with chemotherapy drugs for lung cancer has not changed significantly. Unfortunately, this treatment prolongs the patient's life only by a few months, causing many side effects in the human body. It has also been proven that drugs such as Cisplatin, Carboplatin, Oxaliplatin and others can react with other substances containing an aromatic ring in which the nitrogen atom has a free electron group in its structure.
View Article and Find Full Text PDFWhole-Exome Sequencing Identifies Germline BLM Mutation in Ovarian Hepatoid Adenocarcinoma with Favorable Response to Niraparib and Anlotinib Combination Therapy-A Case Report and Literature Review.
Int J Surg Pathol
July 2024
Department of Gynecology and Obstetrics, West China Second University Hospital of Sichuan University, Chengdu, P.R. China.
Hepatoid adenocarcinoma of the ovary represents a rare and malignant extrahepatic tumor that shares morphological and immunophenotypic similarities with hepatocellular carcinoma. Due to the ambiguous histomorphology and aggressive behavior, the diagnosis and management of hepatoid adenocarcinoma of the ovary present unique challenges. Here, we present a 67-year-old woman with massive ascites and disseminated peritoneal implants at initial diagnosis.
View Article and Find Full Text PDFThe Ability of Clinically Relevant Chemotherapeutics to Induce Immunogenic Cell Death in Squamous Cell Carcinoma.
Front Biosci (Landmark Ed)
April 2024
Cancer Center of Daping Hospital, Third Military Medical University, 400038 Chongqing, China.
Background: Immunogenic cell death (ICD) is a crucial mechanism for triggering the adaptive immune response in cancer patients. Damage-associated molecular patterns (DAMPs) are critical factors in the detection of ICD. Chemotherapeutic drugs can cause ICD and the release of DAMPs.
View Article and Find Full Text PDFComplete response in patient with locally advanced lung large cell neuroendocrine carcinoma under sintilimab plus platinum-based chemotherapy: A case report.
Heliyon
March 2024
State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Article Synopsis
- Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive lung cancer with uncertain treatment options.
- A 66-year-old man with advanced LCNEC showed a positive response to a combined treatment of chemotherapy and immunotherapy before undergoing surgery.
- The case suggests that pre-surgery chemo-immunotherapy could be beneficial for patients with advanced LCNEC, warranting further research on this approach.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!